XNCR Financials: Xencor Inc AI Analysis

Home

Stock

XNCR

Financials

XNCR Financial

Xencor Inc

$12.4

4.28%

$0.5

At close: Mar 25, 16:00:00 GMT-4

$12.4

Post-market: Mar 25, 20:00:00 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$11.89

Open

$12.1

Day's Range

$12.1 - $12.79

52 week range

$6.92 - $18.69

Volume

617.9K

Avg.Volume

727.8K

Dividend yield

EPS (TTM)

-1.88

Market Cap

$909.4M

What is XNCR?

Xencor, Inc. is a biopharmaceutical company, which engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. The company is headquartered in Pasadena, California and currently employs 260 full-time employees. The company went IPO on 2013-12-03. The company has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.



Features

AI Copilot for Stock & Crypto

Resources

Market

Income

Balance sheet

Cash flow

Annual

Quarterly

XNCR Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021
Revenue	125	125	110	174	164	275
Revenue Growth (YoY)	14%	14%	-37%	6%	-40%	125%
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	63	63	61	53	47	38
Research & Development	239	239	227	253	199	192
Operating Expenses	303	303	288	306	247	231
Other Non Operating Income (Expenses)	0	0	0	0	0	0
Pretax Income	-89	-89	-234	-119	-54	82
Income Tax Expense	2	2	1	13	0	0
Net Income	-91	-91	-232	-133	-55	82
Net Income Growth	-61%	-61%	74%	142%	-167%	-219%
Shares Outstanding (Diluted)	74.59	74.23	65.04	60.5	59.7	60.5
Shares Change (YoY)	2%	14%	8%	1%	-1%	6%
EPS (Diluted)	-1.24	-1.23	-3.57	-2.2	-0.93	1.37
EPS Growth	-61%	-65%	63%	137%	-168%	-213%
Free Cash Flow	-138	-138	-211	-99	-18	-32
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	--	--	--	--	--	--
Operating Margin	-141.6%	-141.6%	-161.81%	-75.86%	-50%	15.63%
Profit Margin	-72.8%	-72.8%	-210.9%	-76.43%	-33.53%	29.81%
Free Cash Flow Margin	-110.4%	-110.4%	-191.81%	-56.89%	-10.97%	-11.63%
EBITDA	-167	-167	-166	-121	-74	50
EBITDA Margin	-133.6%	-133.6%	-150.9%	-69.54%	-45.12%	18.18%
D&A For EBITDA	10	10	12	11	8	7
EBIT	-177	-177	-178	-132	-82	43
EBIT Margin	-141.6%	-141.6%	-161.81%	-75.86%	-50%	15.63%
Effective Tax Rate	-2.24%	-2.24%	-0.42%	-10.92%	0%	0%

Follow-Up Questions

What are Xencor Inc's key financial statements?



According to the latest financial statement (Form-10K), Xencor Inc has a total asset of $875, Net loss of $-91

What are the key financial ratios for XNCR?



Xencor Inc's Current ratio is 3.66, has a Net margin is -72.8, sales per share of $1.68.

How is Xencor Inc's revenue broken down by segment or geography?



Xencor Inc largest revenue segment is Engineered Antibody Therapeutics, at a revenue of 110,493,000 in the most earnings release.For geography, United States is the primary market for Xencor Inc, at a revenue of 110,493,000.

Is Xencor Inc profitable?



no, according to the latest financial statements, Xencor Inc has a net loss of $-91

Does Xencor Inc have any liabilities?



yes, Xencor Inc has liability of 239

How many outstanding shares for Xencor Inc?



Xencor Inc has a total outstanding shares of 71.87

Xencor Inc (XNCR) Financial

XNCR Stock Price Chart